


double layered oxcarbazepine tablet does not place one skilled in the art in possession of a single coated tablet as claimed by applicants.

Applicants respectfully request that the amendment to the claims be entered, that the rejection of the claims under 35 U.S.C. 103(a) be withdrawn, and that pending Claims 16-20 be passed to allowance.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6950


John D. Thallemer
Attorney for Applicant
Reg. No. 34,940

Date: August 20, 2002